Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

Sponsor
Sun Yat-sen University
Study ID
NCT05807893
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Bevacizumab
  • Brain Metastases
  • Immunotherapy
  • Non-small Cell Lung Cancer Stage II

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

Study Details

A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases

Key Dates

Start date
May 14, 2023
Status verified
Nov 2024
Primary completion
Mar 22, 2024
Completion
May 15, 2024

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Serplulimab combined with bevacizumab and first-line chemotherapy
    Serplulimab combined with bevacizumab and first-line chemotherapy

Primary Outcome Measure

iPFS [ Time Frame: The time from receipt of study treatment to intracranial tumor PD or to death due to any cause,whichever came first, assessed up to 60 months ]

Related Studies